

Evaluation of Myocardial Viability and Stem Cell Survival - Cardiac Regeneration -

Phillip C. Yang, MD

Associate Professor, Cardiovascular Medicine
Stanford University

CIRM Roundtable with FDA


October 16th, 2012



OVERVIEW

I. Myocardial viability

- Tissue characterization
- Clinical end-point



II. Stem cell survival and engraftment

- Fundamental mechanism for myocardial restoration
- Myocardial regeneration
- Optimal cell population for clinical translation




I. Myocardial Viability

- Coronary artery disease: #1 killer in the US
 - 1.1 million new or recurrent MI and 500,000 deaths
 - Improved acute MI therapy shift in the landscape
- Heart failure (HF): #1 cause of hospital admission
 - Prevalence: 5 million patients
 - Incidence: 300,000 patients/year
 - Advanced therapy: 5-year survival ~50%
 - Heart transplant: 1,000 pt/year
- Accurate diagnosis and optimal therapeutic intervention



Clinical Issues




- Challenge: dysfunctional myocardium
 - Dead, viable, or viable but injured myocardium
 - Sufficient viability to salvage the injured myocardium
 - Revascularization, device, and/or medicine
- Mandate: regenerate the myocardium
 - Permanent and sustained restoration of the myocardium
 - Increase myocardial viability ↔ survival







MRI: Gold Standard

Delayed Gadolinium (Gd) Enhanced MRI (DEMRI)

- Relies on non-specific distribution of Gd into extracellular space
- Delayed Gd clearance from infarcted myocardium/scar produces T1 positive MRI signal



Recovery of Regional Contractility



Kim R, et al. NEJM '00

Clinical End-Point

Journal of Cardiovascular Magnetic Resonance (2006) 8, 773–779
Copyright © 2006 Informa Healthcare
ISSN: 1097-6647 print / 1532-429X online
DOI: 10.1080/10976640600737615

informa
healthcare

Peri-Infarct Ischemia Determined by Cardiovascular Magnetic Resonance Evaluation of Myocardial Viability and Stress Perfusion Predicts Future Cardiovascular Events in Patients with Severe Ischemic Cardiomyopathy

Miwako Tsukiji, MD,¹ Patricia Nguyen, MD,¹ Girish Narayan, MD,¹ Jeffrey Hellinger, MD,² Frandics Chan, MD, PhD,² Robert Herfkens, MD,² John M. Pauly, PhD,³ Michael V. McConnell, MD,¹ and Phillip C. Yang, MD¹

Hypothesis

Presence of peri-infarct ischemia predicts future CVE in patients with severe ischemic cardiomyopathy

(CVE: death, MI, stroke, CHF, ventricular arrhythmia, syncope).



Results: Peri-infarct Ischemia

	CVE (+) (n=6)	CVE (-) (n=17)	<i>p</i>
Peri-infarct ischemia, n (%)	4/6 (67)	2/17 (12)	0.03
Scar volume, cm³	20 ± 15	21 ± 18	NS
Scar percentage of LV volume, %	9 ± 7	15 ± 12	NS
Ejection fraction, %	29 ± 10	23 ± 13	NS
Age, years	51 ± 12	54 ± 11	NS
Coronary anatomy, n (%)			
2 vessel (include P-LAD or LMT)	2/6 (33)	8/17 (47)	NS
3 vessel disease	4/6 (67)	9/17 (53)	NS



Research

Open Access

Quantitative characterization of myocardial infarction by cardiovascular magnetic resonance predicts future cardiovascular events in patients with ischemic cardiomyopathy

Hajime Yokota¹, Shahriar Heidary¹, Chandra K Katikireddy¹, Patricia Nguyen¹, John M Pauly², Michael V McConnell¹ and Phillip C Yang^{*1}

Hypothesis

Quantitative characterization of myocardial scar by CMRI can predict cardiovascular events in patients with severe ischemic cardiomyopathy.

Results: Myocardial Scar

	CVE (+) n=33	CVE (-) n=53	<i>p</i> - value
Scar volume (cm³)	16.8 ± 12.4	11.7 ± 12.6	<u>0.023</u>
Scar % of the myocardium	10.2 ± 6.9	7.2 ± 6.7	<u>0.037</u>



Results: Transmurality

	CVE (+)	CVE (-)	p-value
Non-transmural MI (1- 75% scar of myocardium)	18.4 ± 14.0%	13.8 ± 11.2%	<u>0.049</u>
1 – 25%	9.2 ± 11.0%	6.7 ± 9.3%	0.12
26 – 50%	9.2 ± 10.6%	3.2 ± 3.6%	<u>0.03</u>
51 – 75%	3.5 ± 4.2%	4.0 ± 4.5%	0.30
Transmural MI (76 – 100% scar of myocardium)	5.8 ± 10.2%	7.2 ± 11.4%	0.28



Quantitative Tissue Characterization of Infarct Core and Border Zone in Patients With Ischemic Cardiomyopathy by Magnetic Resonance Is Associated With Future Cardiovascular Events

Shahriar Heidary, MD,* Harendra Patel, MD,* Jaehoon Chung, MD,* Hajime Yokota, MD,* Sandeep N. Gupta, PhD,§ Mihoko V. Bennett, PhD,† Chandra Katikireddy, MD,* Patricia Nguyen, MD,* John M. Pauly, PhD,‡ Masahiro Terashima, MD, PhD,* Michael V. McConnell, MD,* Phillip C. Yang, MD*

Stanford, California; and Niskayuna, New York

Hypothesis

Evaluation of infarct heterogeneity in the peri-infarct region may be a stronger predictor of CVE than the traditional measurements.



Results: Heterogeneity Analysis

Significant predictors for CVE

	CVE (+) n=29	CVE (-) n=41	<i>p</i> -value
Total Scar Mass (g)	36.7 ± 22.2	27.0 ± 21.0	0.03
Peri-Infarct Scar Mass (g)	17.0 ± 13.1	11.2 ± 11.0	0.02
Peri-Infarct Scar % of the Myocardium (%)	10.6 ± 7.9	7.3 ± 7.7	0.04

Medicine vs. revascularization

- Medicine: Peri-infarct zone

Revascularization: Total scar and core zone



Results: LVEF and Volume




	CVE (+)	CVE (-)	<i>p</i> - value
LVEF (%)	25 ± 10	27 ± 13	0.26
LVEDV (ml)	234 ± 76	230 ± 88	0.41
LVESV (ml)	180 ± 73	175 ± 90	0.40




In Vivo Manganese-enhanced MRI (MEMRI)

Manganese-Enhanced MRI (MEMRI)



- Manganese (Mn^{2+}) produces T1 shortening
- Enters **live** cells via L-type Ca^{2+} channels
- Uptake is specific for live cardiomyocytes






MEMRI-DEMRI of Peri-Infarct Region





II. In Vivo MEMRI of Stem Cell Survival




In Vivo MEMRI in Murine Myocardium



Myocardial Regeneration: Human Amniotic Mesenchymal Stem Cells





Stem Cell Profile		Immune Profile		Hematopoietic Profile	
SSEA-3	+	HLA-DR	-	CD34	-
SSEA-4	+	HLA-G	+	CD45	-
TRA 1-81	+	CD59	+	Cardiovascular Profile	
Thy-1 (CD-90)	+			c-kit (CD117)	+



iPSC Generation


- **Around day 10: colony formation**
 - At least ~20 hESC-like colonies were found from 20,000 cells (more than 0.1%)
- **At day 20, the characteristic iPSC colonies were observed**



- high activity of alkaline phosphatases (ALP) was observed.




Immunomodulation *in vivo*

- 250K MiPSCs were injected into hindlimbs of immunocompetent FVB
- MiPSCs survived in the myocardium ~2 weeks
- Week D 1 post-injection;
- MiPSCs survived in FVB mice 7days.




Cardiac Differentiation - Phenotype

- High levels of mature cardiac marker expression: cTnT, connexin 43 and sarcomeric actin
- Calcium transient through L-type calcium channel and contractile force



Calcium Transient Imaging




Atomic Force Microscopy



Functional restoration

- The EF improved by MiPSCs (control NS LVEF 15-20%)
- The myocardial viability was increased significantly (control NS 75%).




Porcine Myocardial Injury Model

8 Adult Farm Pigs




DAY #0: I/R Injury, 1 hr




hAMSC Isolation



hAMSC Preparation




Day 7 Post-IR / Pre-hAMSC




MEMRI: 25-40min



DEMRI 70-80min




Day 0 Intramyocardial hAMSC




~80 million hAMSCs

Serial Cardiac MRI at d7, 14, 21 post-HAMSC




Cardiac PET-CT Imaging



Subpopulation of cells (10-15 million hAMSCs) transduced with HSV-tk PET reporter gene

Immunohistochemistry



Human Anti-Mitochondrial Ab


Helical Catheter




hAMSCs Improve LV Function

Porcine Ischemia-Reperfusion Model


- hAMSCs
- Increased LVEF



Control - 14 d



hAMSC - 14 d




hAMSCs Exhibit Prolonged Survival



Prolonged hAMSC Survival:

- Transduced w/ HSV-tk PET reporter gene
- PET-CT positive for live cell populations within apex and septum, corresponding to hAMSC injection sites
- IHC positive for human Anti-Mitochondrial antibody

d66 post-IR; d38 post-hAMSC






Anti-human Mitochondrial Ab



hAMSCs Increase Viable Myocardium

- hAMSCs generated higher MEMRI signal within the infarct zone: viable hAMSCs
- hAMSCs generated smaller infarct zones
- hAMSCs decreased remodeling



Cardiovascular Stem Cell Imaging

- Evaluation of myocardial viability: **clinical end-point using MEMRI and DEMRI**
 - IND approval for MEMRI
- Translational imaging technique will visualize: **survival of cardiovascular stem cell**
- Permanent and sustained restoration of the injured heart: **myocardial regeneration by optimal cell population**



Laboratory for Cellular and Molecular MRI of Cardiovascular Stem Cells

Yang Laboratory

Takayasu Arai
Jaehoon Chung
Joseph WJ Chung
Xiaohu Ge
Paul Kim
Luke Kwon
Yuka Matsuura
Garren Reichel
Yoriyasu Suzuki
Sean Son
Ildiko Toma
Hunter Wang
Elaine Wang
FACULTY MEMBER
Rajesh Dash

CV Molecular Biology

Thomas Quertermous

CV Imaging

Michael McConnell
Dwight Nishimura
John Pauly
Joe Wu

CT Surgery

Michael Fischbein
Robert Robbins

CV Intervention

Todd Brinton
Alan Yeung

Stem Cell Biology

Oscar Abilez

Julie Baker

John Cooke

Joe Gold

Ngan Huang

Scott Metzler

Renee Reijo-Pera

Chelsey Simmons

Irv Weissman

Funding Source

NIH R01-HL097516-01





R01-HS019738-01

UM1-HL-12026

R01-HL39297

CIRM, CVI SEED, AHA

Direct cardiac transdifferentiation of hAMSCs




VI. Current and Future Clinical Studies

- Direct cardiac transdifferentiation
- Simulation of durable myocardial tissue
- Clinical trial
 - MEMRI FOR MYOCARDIAL VIABILITY: FDA IND
 - NIH Cardiovascular Cell Therapy Research Network
- Disease Modeling of Congenital Heart Disease




Durable Myocardial Tissue


hCMs
only




hCMs +
hAMSCs





hCMs +
hECs






hCMs +
hAMSCs +
hECs




hCMs
only



hCMs + hECs



hAMSC isolation



4. Washing and Digesting the membrane.

Reference: Fabio Marongiu et al. Isolation of Amniotic Mesenchymal Stem Cells. *Current Protocols in Stem Cell Biology* 1E.5.1-1E.5.11



Literature

REVIEW

THE AMERICAN
JOURNAL of
MEDICINE ®

Clinical Relevance of Hibernating Myocardium in Ischemic Left Ventricular Dysfunction

Nov 2010

Arend F.L. Schinkel, MD,^{a,b} Jeroen J. Bax, MD,^c Victoria Delgado, MD,^c Don Poldermans, MD,
Shahbudin H. Rahimtoola, MD^e

Circulation

JOURNAL OF THE AMERICAN HEART ASSOCIATION

American Heart
Association® 
Learn and Live™

**Predicting Benefit From Revascularization in Patients With Ischemic Heart
Failure : Imaging of Myocardial Ischemia and Viability**
Orla Buckley and Marcelo Di Carli


Feb 2011

STANFORD
UNIVERSITY




TANFORD
UNIVERSITY

MEMRI of Myocardial Viability




11:53:40




Dosing 11:42:35



12:16:36





12:35:08



- Rapid assessment of myocardial viability
 - Tissue enhancement pattern established within 30 seconds
 - Persists for at least one hour and blood signal gone by 10 minutes
- Viable cell specific

Mechanism of Delayed Enhancement




- Gd is injected & wait 10-20 min
- Gd accumulates in injured tissue
- 180° RF pulse inverts all the spins
- Tissues return to nl at different rates
- At time TI, image acquisition begins

Mahrholdt, H. et al. Eur Heart J 2005 26:1461-1474

In vivo MEMRI of viable hAMSCs


- hAMSCs survived over 5 weeks (and beyond?) in porcine heart with minimal cyclosporine immunosuppression
- hAMSCs improved cardiac function predictably and durably in subacute and chronic infarction model
- hAMSCs reduced infarct size and LV dilatation
- MEMRI tracked LIVE stem cells with no prior cell modification



D17
Post-
Delivery





Peri-infarct ischemia



Delayed-enhanced

Stress Perfusion Image Peri-infarct Ischemia


Measurement of Myocardial Scar




Scar percentage of the myocardium (%) = Scar volume / myocardial volume



Analysis of Transmurality






1 - 50% (Non transmural)



76 - 100% (Transmural)





Tissue Heterogeneity Quantification






Evaluation Myocardial Viability

- Myocardial Function
 - Echo: safe vs. qualitative and acoustic window
- Cellular Metabolism
 - SPECT and PET: quantitative vs. ionizing radiation and low image quality
- Myocardial Scar and Infarct: gold standard
 - MRI: image quality and quantitative vs. Gd-contrast agent






II. *In Vivo* Evaluation of Stem Cell Survival




	MRI	RN	BLI
Sensitivity	$10^{-7} - 10^{-9}$ Mole/L	$10^{-11} - 10^{-12}$ Mole/L	$10^{-15} - 10^{-17}$ Mole/L
Spatial resolution	500 μm	3-5 mm	3-5mm
Temporal resolution	10 ms	seconds	seconds



In Vivo Molecular MRI - Teratoma




In Vivo Molecular MRI of Cell Survival










STANFORD
UNIVERSITY














In Vivo Molecular MRI of Cell Survival



II. Stem Cell Survival in the Myocardium



Mechanism of Myocardial Restoration



D 2

